We identified CUL5 as a primary molecular target of NAEi therapy and demonstrated that blocking CRL neddylation using NAEi can restore proper Treg function in human Treg assays in vitro and in animal models of autoimmunity in vivo (62). The gene discussed is CUL5; the disease is Autoimmunity.